Adaptive Biotechnologies Corporation
ADPT
$15.40
-$0.72-4.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -23.72% | 59.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -23.72% | 59.60% | |||
| Cost of Revenue | -228.59% | -0.73% | |||
| Gross Profit | 140.59% | 211.40% | |||
| SG&A Expenses | 6.30% | 0.17% | |||
| Depreciation & Amortization | 0.23% | 1.18% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.92% | -0.28% | |||
| Operating Income | -224.13% | 141.10% | |||
| Income Before Tax | -242.26% | 137.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -242.26% | 137.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -100.00% | 104.76% | |||
| Net Income | -242.25% | 137.27% | |||
| EBIT | -224.13% | 141.10% | |||
| EBITDA | -158.37% | 171.56% | |||
| EPS Basic | -241.69% | 137.17% | |||
| Normalized Basic EPS | -244.76% | 137.13% | |||
| EPS Diluted | -253.67% | 135.63% | |||
| Normalized Diluted EPS | -254.64% | 134.76% | |||
| Average Basic Shares Outstanding | 0.46% | 0.23% | |||
| Average Diluted Shares Outstanding | -6.15% | 7.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||